Literature DB >> 25921670

Locoregional therapy of hepatocellular carcinoma.

Ali Habib1, Kush Desai1, Ryan Hickey1, Bartley Thornburg1, Robert Lewandowski1, Riad Salem2.   

Abstract

Hepatocellular carcinoma can be treated using minimally invasive, image-guided, catheter-based or percutaneous techniques. Such procedures offer compelling clinical outcomes with a favorable side-effect profile in a population of patients who are poor candidates for surgical or systemic treatment. This article discusses key data regarding the effectiveness of locoregional therapies in treating these patients. Disease-specific treatment is discussed in the context of hepatocellular carcinoma, with additional data discussed in the context of transplantation. As rapid innovation occurs in the realm of oncology, interventional oncology represents a safe, effective alternative that continues to generate impressive data that could potentially change treatment paradigms.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Interventional oncology; Locoregional therapies; Percutaneous ethanol injection; Radioembolization; Radiofrequency ablation; Transarterial chemoembolization; Transplantation

Mesh:

Substances:

Year:  2015        PMID: 25921670     DOI: 10.1016/j.cld.2015.01.008

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  8 in total

1.  Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.

Authors:  Rusi Zhang; Lujun Shen; Long Zhao; Zhaoming Guan; Qifeng Chen; Wang Li
Journal:  Diagn Interv Radiol       Date:  2018-07       Impact factor: 2.630

Review 2.  Current State of Tumor Ablation Therapies.

Authors:  Christopher W Bailey; Malcolm K Sydnor
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation.

Authors:  Maria Baimas-George; Michael Watson; Jesse Sulzer; Patrick Salibi; Keith J Murphy; David Levi; John B Martinie; Dionisios Vrochides; Erin H Baker; Lee Ocuin; David A Iannitti
Journal:  Surg Endosc       Date:  2020-06-25       Impact factor: 4.584

4.  Same-day 90Y radioembolization: implementing a new treatment paradigm.

Authors:  Ahmed Gabr; Joseph Ralph Kallini; Vanessa L Gates; Ryan Hickey; Laura Kulik; Kush Desai; Bartley Thornburg; Karen Marshall; Krystina Salzig; Melissa Williams; Carlene Del Castillo; Daniel Ganger; Elias Hohlastos; Talia Baker; Robert J Lewandowski; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-17       Impact factor: 9.236

5.  The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma.

Authors:  Lunxu Li; Shilin Xia; Xueying Shi; Xu Chen; Dong Shang
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

Review 6.  Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources.

Authors:  Dong Ho Lee; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

7.  A Novel Approach to Deliver Therapeutic Extracellular Vesicles Directly into the Mouse Kidney via Its Arterial Blood Supply.

Authors:  Mujib Ullah; Daniel D Liu; Sravanthi Rai; Mehdi Razavi; Jeff Choi; Jing Wang; Waldo Concepcion; Avnesh S Thakor
Journal:  Cells       Date:  2020-04-10       Impact factor: 6.600

Review 8.  Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature.

Authors:  Teresa Marzia Rogger; Andrea Michielan; Sandro Sferrazza; Cecilia Pravadelli; Luisa Moser; Flora Agugiaro; Giovanni Vettori; Sonia Seligmann; Elettra Merola; Marcello Maida; Francesco Antonio Ciarleglio; Alberto Brolese; Giovanni de Pretis
Journal:  World J Gastroenterol       Date:  2020-09-21       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.